+1.925.223.6233

In fact, Overall, Choosing a dependable online casino demands calm judgement, because the conditions shape the experience much more bold slogans. Keep in mind that To get a practical starting point, many readers frequently look at blik online casino, assuming they study the details carefully. Also, Welcome offers look tempting, yet their real value rests on the wagering terms, which deserve a close look. Banking methods need to be convenient, and the withdrawal speed is usually one of the most telling signs of a fair brand. Also, The range of titles tends to be broad, from video slots to roulette, giving players real choice. Also, Live dealer play appeals to players with real-time streams, and the stream quality shape the whole atmosphere. Also, A responsive help desk makes the difference whenever questions arise, especially if live chat are on hand. Also, Payouts reveal the true character behind a casino, so clear limits and quick processing build confidence. Also, Sensible gaming should stay central, so reality checks and clear budgets truly protect the user. Moreover, Besides, A proper licence is the essential thing to verify, because it shows that the platform respects clear requirements. Moreover, Besides, Promotions draw attention, yet their true worth depends on the playthrough conditions, which reward a calm review. Besides, Deposit choices ought to be flexible, and the payout time is often one of the clearest marks of a serious site. Moreover, Besides, The selection is generally wide, from classic slots to baccarat, offering fans plenty of options. Moreover, Besides, A live lobby attracts users with real dealers, and the betting limits define the entire session. Moreover, Besides, Good customer service sets the standard when problems show up, particularly if clear answers are easy to reach. Moreover, Besides, Cash-outs show the real nature of a casino, so reasonable checks and prompt handling inspire loyalty. Moreover, Besides, Safer gambling has to stay a priority, so deposit limits and calm habits really support the account holder. Moreover, Furthermore, A proper licence is the key thing to confirm, because it shows that the platform follows clear rules. Moreover, Furthermore, Promotions catch the eye, yet their actual benefit depends on the playthrough conditions, which deserve a calm read. When all is said and done, All in all, a thoughtful choice rests on clear terms, so compare calmly, check the rules and keep control. Uma boa referência costuma ser cassinos estrangeiros online, desde que você verifique os detalhes do site, ao invés de apenas ao visual do site. A seção ao vivo cativa o público devido aos crupiês profissionais, sendo que a qualidade do stream determina a imersão do jogador de forma significativa a cada rodada. O atendimento faz diferença, sobretudo quando aparecem problemas, portanto uma resposta rápida deve estar disponível 24 horas por dia, proporcionando uma experiência tranquila em qualquer situação. A agilidade dos pagamentos reflete a qualidade do serviço, portanto termos claros de retirada indicam qualidade a longo prazo para o jogador. O entretenimento controlado precisa ser o foco principal, portanto limites de depósito efetivamente promovem hábitos saudáveis de maneira eficaz no longo prazo. O registro regulatório é o sinal mais claro de confiança, pois assegura regras claras, o que merece atenção antes do cadastro, idealmente com atenção. As promoções chamam atenção, mas seu valor real esconde-se nos detalhes, por isso vale a pena ler cada exigência sem pressa. As formas de depósito devem ser variados e confiáveis, e a velocidade das transações geralmente indica o nível da plataforma, aspecto que deve ser avaliado antes de se cadastrar. A biblioteca de títulos costuma ser rico em opções, desde jogos de máquina até pôquer e bacará, o que contempla todo tipo de usuário. O cassino ao vivo atrai jogadores devido aos dealers reais, pois a qualidade do stream determina a experiência de jogo consideravelmente em cada partida. A assistência ao usuário tem grande valor, especialmente quando aparecem problemas, por isso um atendimento eficiente deve estar disponível 24 horas por dia, garantindo uma jogada confortável a todo momento. A velocidade dos saques reflete a seriedade da plataforma, então termos claros de retirada geram confiança de forma consistente para o usuário. O jogo responsável precisa ser uma prioridade, então limites de depósito efetivamente protegem o jogador com resultados positivos na rotina de apostas. O registro regulatório representa o sinal mais claro de confiança, pois confirma a fiscalização, o que traz tranquilidade logo no início, preferencialmente sem pressa. As promoções são atrativos, mas seu valor real depende das condições de apostas, por isso é preciso verificar as condições detalhadamente antes de aceitar. Por fim a decisão certa vem de análise, então pesquise com atenção, verifique os termos e condições e estabeleça seus limites. K tomu, Praktickym prikladem je vetsinou mobilní casino Česko, za predpokladu ze posoudite to v klidu, misto duvery v reklamu, celkem rozumne. Dale, Aktualni licence je temer vzdy klicovy prvek bezpeci, ponevadz zarucuje jasna pravidla, co netreba prehlizet hned na zacatku. Dale, Akce delaji dojem, nicmene jejich opravdovy zisk plyne z podminek, proto je je treba precist bez spechu. Dale, Zpusoby vkladu by mely byt flexibilni, a soucasne doba zpracovani zpravidla svedci o poctivosti, cemu venujte pozornost. Navic, Nabidka her obvykle je pestra, od her s jackpotem po bakarat, a tim zajistuje pestrost na dlouho. Dale, Rezim live dela dojem diky autenticke atmosfere, a pritom rozsah sazek rozhoduje o zazitku kazde partie. Dale, Dobra zakaznicka podpora buduje duveru, zejmena kdyz neco je treba vysvetlit, a tak by jasna vysvetleni maji cenu zlata v pripade potreby. Dale, Vyplaceni vyher prozrazuji pravdu o kvality sluzby, a tak rychle zpracovani davaji klid casem. Dale, Bezpecne hrani vzdy ma vyznam, a tak moznost sebevylouceni citelne pomahaji zachovat rozum bezne. Krome toho, Aktualni licence je vzdy prvni vec ke kontrole, jelikoz dokazuje legalitu, co netreba prehlizet jeste pred vkladem. Krome toho, Akce pritahuji pozornost, avsak jejich realny prinos se skryva v pravidlech, proto je je treba precist pozorne. Krome toho, Zpusoby vkladu by mely byt bezpecne, a rychlost vyplat obvykle svedci o poctivosti, co lze snadno prehlednout. Herni knihovna obvykle je bohata, od klasickych automatu po blackjack, cimz zajistuje pestrost bez nudy. Krome toho, Rezim live budi emoce diky skutecnym krupierum, a zaroven pocet stolu rozhoduje o zazitku vecera u hry. Krome toho, Dobra zakaznicka podpora ma velky vyznam, zejmena kdyz vyvstanou otazky, a proto by rychle odpovedi maji cenu zlata kdykoli. Krome toho, Vyplaceni vyher nejvic vypovidaji o poctivosti kasina, a proto rozumne podminky davaji klid kazdy den. Krome toho, Bezpecne hrani musi zustat dulezita, proto pripominky casu opravdu pomahaji zachovat rozum z dlouhodobeho hlediska. Platna licence je zpravidla klicovy prvek bezpeci, protoze potvrzuje dohled regulatora, co netreba prehlizet nez zacnete hrat. Bonusy vypadaji atraktivne, nicmene jejich skutecna hodnota zavisi na podminkach sazeni, proto je je treba precist s rozvahou. Platebni metody by mely byt rychle, a soucasne doba vyplaty casto svedci o poctivosti, co dela rozdil. Nabidka her byva impozantni, od her s jackpotem po ruletu, coz zajistuje pestrost kdykoli. Celkove, V dusledku uvazene rozhodnuti vychazi z analyzy, takze porovnavejte s chladnou hlavou, ctete pozorne pravidla a stanovte si limity. 安な カジノ を 利用する 際 には 丁寧 に 確認 する こと が 重要 です、なぜなら 条件 の 詳細 が 選択 を 大きく 決める から; 常に 詳細 を 丁寧 に 分析 し てから 金 する の が 賢明 です。 また、信頼できる 候補 として は よく 知られている オンラインカジノ 本人確認不要、条件 として 落ち着いて 条件 を 比較 すれ ば、最適 な 判断 が でき ます。 また、なお、その他にも、各種 キャンペーン は 目を 引き ます、ただし 実際 の 価値 は 条件 の 中 に あります。そのため 重 に 詳細 を 確かめ てから 受け取る こと を お勧め します。 また、決済 オプション は 多様 で 安 で ある べき です。取引 の 完了 スピード は 多く の 場合 運営 の 姿勢 を 表します。これ は プレイ 開始 前 に 確認 する 価値 が ある 重要 な 点 です。 その上、さらに、コンテンツ の 実度 は 一般 的 に 非常 に 豊富 で 多様 です。人気 の スロット から ルーレット や ブラックジャック まで、異なる 好み の 利用 に 対応 して います。 加えて、なお、ライブ カジノ は ライブ 信 の おかげ で 多く の プレイヤー を 了 します。映像 の スムーズさ が 没感 を 大きく 左右 します。 また、ユーザー サポート は 特 に 助け が 要 な とき に 大きな 差 を 生み ます。効率 的 な サポート が 要 な とき に 利用 できる こと が 重要 です。 加えて、なお、出金 の 速さ は 運営 の 姿勢 を 最も よく 示します。わかりやすい 取引 条件 が 長期 的 な 信頼 を 築き ます。 なお、さらに、コントロール された 娯楽 は 優 事 で ある べき です。支出 管理 機能 の 利用 が バランス の とれた 生活 を 促し 長期 的 に 役立ち ます。 加えて、また、なお、正規 の ライセンス は 通常 最も 明確 な 信頼 の 証 で あり、それ は 規制 当局 の 監督 を 確認 する から。これ は 初回 金 前 に 丁寧 に 確認 すべき 大切 な 事 です。 また、さらに、特 の 数 は 目を 引き ます、しかし 本当 の メリット は 条件 の 中 に あります。そのため じっくり と 条件 を 確認 し てから 判断 する の が 賢明 です。 その上、その他にも、 出金 方法 は 便利 で 信頼できる べき です。取引 の 完了 スピード は 多く の 場合 カジノ の レベル を 示します。これ は 登録 前 に チェック しておく べき ポイント です。 加えて、また、なお、コンテンツ の 実度 は 通常 実 しており 選択肢 が 豊富 です。人気 の スロット から ルーレット や ブラックジャック まで、多様 な ニーズ の ユーザー に 合わせて います。 最終的 に は 最適 な 判断 は 事実 に 基づく もの です。そのため 重 に 評価 し、条件 を 検証 し、コントロール を 保ち ながら 楽しむ こと が 大切 です。 Overall, Choosing a trustworthy online casino takes careful thought, because the details truly matter much more bold slogans. Importantly, Keep in mind that To get a solid starting point, many readers often look at best bitcoin casino australia, assuming they read the terms carefully. Furthermore, The game library is usually wide, from classic slots to blackjack, offering fans genuine variety. Furthermore, A live casino draws in users with real dealers, and the table range define the entire experience. Furthermore, Helpful support marks the standard when issues appear, particularly if clear answers are available. Furthermore, Withdrawals expose the real nature of a casino, so fair terms and prompt handling inspire trust. Furthermore, Responsible play must remain a priority, so deposit limits and firm rules really support the player. A valid licence is the first thing to confirm, because it shows that the casino follows firm standards. Bonuses look tempting, yet their actual benefit depends on the rollover rules, which deserve a careful look. Payment options should be convenient, and the cash-out period is often one of the most useful signs of a honest brand. The game library tends to be generous, from classic slots to blackjack, giving users real choice. A live casino appeals to fans with real dealers, and the table range shape the overall atmosphere. Helpful support makes the tone when issues appear, especially if quick replies are on hand. Withdrawals reveal the honest side of a casino, so fair terms and quick processing earn confidence. Responsible play should stay in focus, so deposit limits and firm rules truly safeguard the user. Moreover, In addition, A valid licence is the first thing to check, because it shows that the operator meets strict requirements. Moreover, In addition, Bonuses look tempting, yet their real value depends on the wagering terms, which repay a close review. Besides, Banking methods should be convenient, and the withdrawal speed is often one of the most telling indicators of a fair site. Moreover, In addition, The game library tends to be broad, from classic slots to roulette, bringing players plenty of options. Moreover, In addition, A live casino appeals to players with real dealers, and the stream quality drive the whole session. To summarize, When all is said and done, All in all, a sensible choice rests on facts, so compare calmly, read closely and keep control. Em geral, Uma opção interessante pode ser casa de aposta sem verificação de identidade, desde que você verifique as condições disponíveis, ao invés de apenas ao visual da plataforma. O catálogo de jogos é normalmente diversificado e atrativo, incluindo desde caça-níqueis tradicionais até pôquer e bacará, o que agrada variados gostos. A seção ao vivo cativa o público por conta dos crupiês profissionais, sendo que a qualidade do stream determina a experiência de jogo de forma significativa durante toda a sessão. A assistência ao usuário faz diferença, sobretudo quando é preciso ajuda, portanto uma resposta rápida deve estar disponível 24 horas por dia, garantindo uma experiência tranquila quando precisar. A agilidade dos pagamentos demonstra a qualidade do serviço, portanto termos claros de retirada geram confiança a longo prazo para quem aposta. O entretenimento controlado tem que ser o foco principal, portanto limites de depósito efetivamente protegem o jogador de maneira eficaz ao longo do tempo. O registro regulatório é a garantia básica de proteção, pois assegura regras claras, o que traz tranquilidade logo no início, de preferência com calma. As promoções chamam atenção, contudo seu valor real esconde-se nos detalhes, por isso é preciso verificar os termos com cuidado com calma. As formas de depósito devem ser ágeis e protegidos, e a velocidade das transações geralmente revela a qualidade do serviço, fator que merece atenção antes de depositar. A biblioteca de títulos costuma ser diversificado e atrativo, desde jogos de máquina até roleta e blackjack, isso agrada diferentes perfis de jogadores. O cassino ao vivo atrai jogadores por conta dos dealers reais, pois a qualidade do stream define a imersão do jogador de forma significativa a cada rodada. O suporte ao cliente tem grande valor, especialmente quando é preciso ajuda, por isso um atendimento eficiente deve estar disponível a qualquer hora, proporcionando uma experiência tranquila em qualquer situação. A velocidade dos saques demonstra a seriedade da plataforma, então termos claros de saque indicam qualidade a longo prazo para o jogador. O jogo responsável tem que ser uma prioridade, então limites de depósito realmente promovem hábitos saudáveis de maneira eficaz no longo prazo. O registro regulatório representa a garantia básica de proteção, pois confirma a fiscalização, o que traz tranquilidade antes do cadastro, idealmente com atenção. Dito isso, Em resumo uma seleção acertada vem de análise, então avalie com cuidado, verifique os termos e condições e mantenha o controle. Merita attenzione di regola casino online stranieri, solo quando verifichi la licenza, invece di credere alla pubblicita, con la dovuta attenzione, per valutare ogni aspetto. Il gioco responsabile deve restare importante, percio gli avvisi sul tempo danno un senso di controllo in ogni momento, senza perdere equilibrio prima di decidere. Una licenza valida e quasi sempre l elemento chiave di sicurezza, perche conferma la vigilanza, cosa da non ignorare prima di registrarti, con attenzione prima della scelta. I bonus fanno impressione, ma il loro guadagno effettivo dipende dal rollover, percio conviene leggerli con calma, in modo chiaro prima della scelta. I metodi di pagamento dovrebbero essere flessibili, e la durata del processo spesso riflette l onesta, cosa da verificare, in modo chiaro prima della scelta. Inoltre, La libreria di giochi di solito e variata, da giochi con jackpot fino a roulette, il che assicura varieta ogni giorno, con valutazioni attente prima della scelta. Il casino dal vivo fa impressione grazie a un atmosfera autentica, e la qualita dello stream decide l esperienza dell intera sessione, in modo evidente prima della scelta. Un assistenza cortese crea fiducia, soprattutto quando qualcosa va chiarito, percio la chat dal vivo valgono oro in ogni momento, con risposte precise prima della scelta. I prelievi rivelano la verita su la qualita del servizio, percio limiti chiari danno tranquillita a lungo termine, con effetti visibili prima della scelta. Un approccio prudente conta sempre, percio i limiti di deposito aiutano a mantenere la lucidita ogni giorno, con attenzione costante prima della scelta. Una licenza affidabile e di solito l elemento chiave di sicurezza, perche garantisce regole chiare, cio che da tranquillita prima di registrarti, con attenzione durante il confronto. I premi iniziali sono allettanti, ma il loro guadagno effettivo deriva dal regolamento, percio vanno verificati con calma, in modo chiaro durante il confronto. Le opzioni di incasso dovrebbero essere comodi, e la durata del processo in genere rivela l approccio dell operatore, cosa da verificare, in modo chiaro durante il confronto. La libreria di giochi si presenta ampia, da giochi con jackpot fino a baccara, il che accontenta giocatori diversi ogni giorno, con valutazioni attente durante il confronto. In breve una decisione consapevole poggia sui numeri, quindi non avere fretta, leggi con attenzione le regole e usa il buon senso, in qualsiasi momento.
 

14 May Apellis Announces U.S. Food and Drug Administration (FDA) Approval of EMPAVELI™ (pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Posted at 13:09h in News by
0 Likes
  • EMPAVELI, the first targeted C3 therapy, is approved for use in adults with PNH who are:
    • Treatment naïve
    • Switching from C5 inhibitor Soliris® (eculizumab)
    • Switching from C5 inhibitor Ultomiris® (ravulizumab)
  • EMPAVELI was superior to Soliris for the change from baseline in hemoglobin level at Week 16 in the Phase 3 PEGASUS study
  • 85% of patients treated with EMPAVELI were transfusion free compared to 15% on Soliris at Week 16; EMPAVELI met non-inferiority compared to Soliris on transfusion avoidance
  • Apellis to host investor conference call on Monday, May 17 at 8:00 a.m. ET

WALTHAM, Mass., May 14, 2021 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved EMPAVELI™ (pegcetacoplan), the first and only targeted C3 therapy for treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH). EMPAVELI is approved for use in adults with PNH who are treatment naïve as well as patients switching from the C5 inhibitors Soliris® (eculizumab) and Ultomiris® (ravulizumab).

“EMPAVELI has the potential to improve the lives of patients with PNH by increasing hemoglobin and reducing blood transfusion requirements,” said Olga Frankfurt, M.D., PEGASUS study investigator and associate professor in the department of medicine, division of hematology and oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University. “Through my work as an investigator on the PEGASUS study, I was excited to see EMPAVELI providing broad control of PNH.”

“As the first, FDA-approved targeted C3 therapy, EMPAVELI has the potential to redefine treatment for adults with PNH, including patients switching from any C5 inhibitor and treatment-naïve patients. Thank you to the clinical trial participants, PNH community, investigators, healthcare professionals, SFJ Pharmaceuticals, and more who helped contribute to this significant milestone,” said Cedric Francois, M.D., Ph.D., co-founder and chief executive officer, Apellis. “This approval represents a major scientific advancement as EMPAVELI ushers in the first new class of complement medicine in almost 15 years. We look forward to exploring the full potential of targeting C3 and continue to advance registrational programs of this therapy across multiple complement-driven diseases with high unmet need.”

The approval of EMPAVELI is based on results from the head-to-head Phase 3 PEGASUS study, which were recently published in the New England Journal of Medicine. In the PEGASUS study, EMPAVELI met the primary endpoint, demonstrating superiority to Soliris for the change from baseline in hemoglobin level at Week 16 with an adjusted mean increase of 3.84 g/dL of hemoglobin (p<0.0001). Additionally, EMPAVELI met non-inferiority compared to Soliris on the endpoint of transfusion avoidance. Eighty five percent of EMPAVELI-treated patients were transfusion free over 16 weeks versus 15% of Soliris-treated patients.

“We are pleased to hear of the FDA’s decision to approve EMPAVELI, which is an important milestone for patients,” said Janice Frey-Angel, chief executive officer and executive director, Aplastic Anemia and MDS International Foundation (AAMDSIF). “Many PNH patients are seeking choices in their treatment, so the approval brings new promise for the PNH community.”

The prescribing information for EMPAVELI contains a boxed warning. EMPAVELI may increase the risk of meningococcal and other serious infections caused by encapsulated bacteria that may become rapidly life threatening or fatal if not recognized and treated early. A Risk Evaluation and Mitigation Strategy (REMS) has been approved by the FDA for EMPAVELI. Prescribers must counsel patients about the risk of serious infection, provide patients with the REMS educational materials, and ensure patients are vaccinated against encapsulated bacteria.

The most common serious adverse reaction in patients treated with EMPAVELI was infections (5%). The most common adverse reactions (≥10%) with EMPAVELI were injection site reactions (39%), infections (29%), diarrhea (22%), abdominal pain (20%), respiratory tract infection (15%), viral infection (12%), and fatigue (12%). No cases of meningitis and no deaths were reported in patients treated with EMPAVELI.

PNH is a rare, chronic, life-threatening blood disorder caused by an acquired mutation, which leads to uncontrolled complement activation and the destruction of red blood cells through intravascular and extravascular hemolysis. According to a retrospective and a cross-sectional study of patients treated with C5 inhibitors, at least 72% had persistently low hemoglobin1,2 and at least 36% required one or more transfusions a year.1

Apellis is committed to helping patients with treatment access and support. ApellisAssist™ is a program designed to provide comprehensive product support to EMPAVELI patients throughout their treatment journey. This program provides services and product resources including insurance support, education, training, as well as financial assistance for eligible patients. Patients and healthcare providers can contact 1-866-692-7527 for more information.

A Marketing Authorization Application for pegcetacoplan for the treatment of PNH is under review by the European Medicines Agency with the potential for a European Commission decision in the second half of 2021.

Conference Call and Webcast
Apellis will host a conference call and webcast to discuss the U.S. Food and Drug Administration (FDA) approval of EMPAVELI™ (pegcetacoplan) on Monday, May 17 at 8:00 a.m. ET. To access the live call by phone, please dial 866-774-0323 (domestic) or 602-563-8683 (international); the conference ID is 3239157. A live audio webcast of the event and accompanying slides may also be accessed through the “Events and Presentations” page of the “Investors and Media” section of the company’s website at http://investors.apellis.com/events-and-presentations. A replay of the webcast will be available for 30 days following the event.

About the PEGASUS Study
The PEGASUS study (APL2-302; NCT03500549) is a multi-center, randomized, head-to-head Phase 3 study in 80 adults with paroxysmal nocturnal hemoglobinuria (PNH). The primary objective of this study was to establish the efficacy and safety of EMPAVELI™ (pegcetacoplan) compared to Soliris® (eculizumab). Participants must have been on Soliris (stable for at least three months) with a hemoglobin level of <10.5 g/dL at the screening visit. During the four-week run-in, patients were dosed with 1080 mg of EMPAVELI twice weekly (n=41) in addition to their current dose of Soliris. During the 16-week randomized, controlled period, patients were randomized to receive either 1080 mg of EMPAVELI twice weekly or their current dose of Soliris (n=39). All participants completing the randomized controlled period (n=77) opted to enter the open-label EMPAVELI treatment period.

The study was conducted in collaboration with SFJ Pharmaceuticals, who supported the development of EMPAVELI in PNH. SFJ is a global drug development company, which provides a unique and highly customized co-development partnering model for the world’s top pharmaceutical and biotechnology companies.

About EMPAVELI™ (pegcetacoplan)
EMPAVELI™ (pegcetacoplan) is the first and only approved therapy targeting C3, the central protein in the complement cascade. EMPAVELI acts proximally in the complement cascade controlling both C3b-mediated extravascular hemolysis and terminal complement-mediated intravascular hemolysis. EMPAVELI is approved in the United States for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH).

U.S. Important Safety Information for EMPAVELI

BOXED WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA

  • Meningococcal infections may occur in patients treated with EMPAVELI and may become rapidly life-threatening or fatal if not recognized and treated early. Use of EMPAVELI may predispose individuals to serious infections, especially those caused by encapsulated bacteria, such as Streptococcus pneumoniae, Neisseria meningitidis types A, C, W, Y, and B, and Haemophilus influenzae type B.
  • Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccinations against encapsulated bacteria.
  • Vaccinate patients at least 2 weeks prior to administering the first dose of EMPAVELI unless the risks of delaying therapy with EMPAVELI outweigh the risk of developing a serious infection.
  • Vaccination reduces, but does not eliminate, the risk of serious infections. Monitor patients for early signs of serious infections and evaluate immediately if infection is suspected.
  • EMPAVELI is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS). Under the EMPAVELI REMS, prescribers must enroll in the program.

CONTRAINDICATIONS

  • Hypersensitivity to pegcetacoplan or to any of the excipients
  • Not currently vaccinated against certain encapsulated bacteria, unless the risks of delaying EMPAVELI treatment outweigh the risks of developing a bacterial infection with an encapsulated organism
  • Unresolved serious infection caused by encapsulated bacteria including Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae

WARNINGS AND PRECAUTIONS

Serious Infections Caused by Encapsulated Bacteria
The use of EMPAVELI may predispose individuals to serious, life-threatening, or fatal infections caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria meningitidis types A, C, W, Y, and B, and Haemophilus influenzae type B (Hib). To reduce the risk of infection, all patients must be vaccinated against these bacteria according to the most current ACIP recommendations for patients with altered immunocompetence associated with complement deficiencies. Revaccinate patients in accordance with ACIP recommendations considering the duration of therapy with EMPAVELI.

For patients without known history of vaccination, administer required vaccines at least 2 weeks prior to receiving the first dose of EMPAVELI. If immediate therapy with EMPAVELI is indicated, administer required vaccine as soon as possible and provide patients with 2 weeks of antibacterial drug prophylaxis.

Closely monitor patients for early signs and symptoms of serious infection and evaluate patients immediately if an infection is suspected. Promptly treat known infections. Serious infection may become rapidly life-threatening or fatal if not recognized and treated early. Consider discontinuation of EMPAVELI in patients who are undergoing treatment for serious infections.

EMPAVELI REMS
Because of the risk of serious infections, EMPAVELI is available only through a restricted program under a REMS. Under the EMPAVELI REMS, prescribers must enroll in the program and must counsel patients about the risk of serious infection, provide the patients with the REMS educational materials, and ensure patients are vaccinated against encapsulated bacteria. Enrollment and additional information are available by telephone: 1-888-343-7073 or at www.empavelirems.com.

Infusion-Related Reactions
Systemic hypersensitivity reactions (e.g., facial swelling, rash, urticaria) have occurred in patients treated with EMPAVELI. One patient (less than 1% in clinical studies) experienced a serious allergic reaction which resolved after treatment with antihistamines. If a severe hypersensitivity reaction (including anaphylaxis) occurs, discontinue EMPAVELI infusion immediately, institute appropriate treatment, per standard of care, and monitor until signs and symptoms are resolved.

Monitoring PNH Manifestations after Discontinuation of EMPAVELI
After discontinuing treatment with EMPAVELI, closely monitor for signs and symptoms of hemolysis, identified by elevated LDH levels along with sudden decrease in PNH clone size or hemoglobin, or reappearance of symptoms such as fatigue, hemoglobinuria, abdominal pain, dyspnea, major adverse vascular events (including thrombosis), dysphagia, or erectile dysfunction. Monitor any patient who discontinues EMPAVELI for at least 8 weeks to detect hemolysis and other reactions. If hemolysis, including elevated LDH, occurs after discontinuation of EMPAVELI, consider restarting treatment with EMPAVELI.

Interference with Laboratory Tests
There may be interference between silica reagents in coagulation panels and EMPAVELI that results in artificially prolonged activated partial thromboplastin time (aPTT); therefore, avoid the use of silica reagents in coagulation panels.

ADVERSE REACTIONS
The most common adverse reactions (incidence ≥10% of patients) with EMPAVELI vs. eculizumab were injection-site reactions (39% v. 5%), infections (29% v. 26%), diarrhea (22% v. 3%), abdominal pain (20% v. 10%), respiratory tract infection (15% v. 13%), viral infection (12% v. 8%), and fatigue (12% v. 23%).

USE IN SPECIFIC POPULATIONS

Females of Reproductive Potential
EMPAVELI may cause embryo-fetal harm when administered to pregnant women. Pregnancy testing is recommended for females of reproductive potential prior to treatment with EMPAVELI. Advise female patients of reproductive potential to use effective contraception during treatment with EMPAVELI and for 40 days after the last dose.

Please see full Prescribing Information, including Boxed WARNING regarding serious infections caused by encapsulated bacteria, and Medication Guide.

About the Apellis and Sobi Collaboration
Apellis and Sobi entered a collaboration to develop and commercialize systemic pegcetacoplan in October 2020. The companies have global co-development rights for systemic pegcetacoplan. Apellis has exclusive U.S. commercialization rights for systemic pegcetacoplan and retains worldwide commercial rights for ophthalmological pegcetacoplan, including for geographic atrophy (GA). Sobi has exclusive ex-U.S. commercialization rights for systemic pegcetacoplan.

About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, we aim to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. For more information, please visit http://apellis.com.

Apellis Forward-Looking Statement
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements in respect of the expected closing of the exchanges. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether the conditions for the closing of the exchanges will be satisfied and other factors discussed in the “Risk Factors” section of Apellis’ Quarterly Report on Form 10-Q with the Securities and Exchange Commission on April 28, 2021 and the risks described in other filings that Apellis may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contacts:

Media:
Lissa Pavluk
media@apellis.com
617.977.6764

Investors: 
Argot Partners
apellis@argotpartners.com
212.600.1902

1.  McKinley C. Extravascular Hemolysis Due to C3-Loading in Patients with PNH Treated with Eculizumab: Defining the Clinical Syndrome. Blood. 2017;130:3471.
2. Dingli ASH 2020 Abstract/ p.1/ Methods/ ln.1-2; p.2/ Results/ln.7-9; ln.14-15.